Pilot study on the use of DNA priming immunization to enhance Y. pestis LcrV-specific B cell responses elicited by a recombinant LcrV protein vaccine

Vaccines

Volumn 2, Issue 1, 2014, Pages 36-48

  Li, Wei ^a   Wang, Shixia ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

DNA vaccine; Memory B cell; V antigen; Yersinia pestis

Indexed keywords

DNA VACCINE; IMMUNOGLOBULIN G; LCRV IMMUNOGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW CELL; CONTROLLED STUDY; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE GUN IMMUNIZATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MEMORY CELL; MOUSE; NONHUMAN; PLAGUE; SPLEEN CELL; VACCINATION; YERSINIA PESTIS;

EID: 84963648573     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2010036     Document Type: Article

References (32)

1. Wang, S.; Kennedy, J.S.; West, K.; Montefiori, D.C.; Coley, S.; Lawrence, J.; Shen, S.; Green, S.; Rothman, A.L.; Ennis, F.A. et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008, 26, 3947-3957.
2. Vaine, M.; Wang, S.; Crooks, E.T.; Jiang, P.; Montefiori, D.C.; Binley, J.; Lu, S. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J. Virol. 2008, 82, 7369-7378.
3. Vaine, M.; Wang, S.; Hackett, A.; Arthos, J.; Lu, S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010, 28, 2999-3007.
4. Vaine, M.; Wang, S.; Liu, Q.; Arthos, J.; Montefiori, D.; Goepfert, P.; McElrath, M.J.; Lu, S. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One 2010, 5, e13916.
5. Wang, S.; Heilman, D.; Liu, F.; Giehl, T.; Joshi, S.; Huang, X.; Chou, T.H.; Goguen, J.; Lu, S. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 2004, 22, 3348-3357.
6. Wang, S.; Joshi, S.; Mboudjeka, I.; Liu, F.; Ling, T.; Goguen, J.D.; Lu, S. Relative immunogenicity and protection potential of candidate Yersinia pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine 2008, 26, 1664-1674.
7. +T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine 2011, 29, 6802-6809.
8. Ledgerwood, J.E.; Wei, C.J.; Hu, Z.; Gordon, I.J.; Enama, M.E.; Hendel, C.S.; McTamney, P.M.; Pearce, M.B.; Yassine, H.M.; Boyington, J.C. et al. DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 2011, 11, 916-924.
9. Cleri, D.J.; Vernaleo, J.R.; Lombardi, L.J.; Rabbat, M.S.; Mathew, A.; Marton, R.; Reyelt, M.C. Plague pneumonia disease caused by Yersinia pestis. Semin. Respir. Infect. 1997, 12, 12-23.
10. Josko, D. Yersinia pestis: Still a plague in the 21st century. Clin. Lab. Sci. 2004, 17, 25-29.
11. Chanteau, S.; Ratsitorahina, M.; Rahalison, L.; Rasoamanana, B.; Chan, F.; Boisier, P.; Rabeson, D.; Roux, J. Current epidemiology of human plague in madagascar. Microbes Infect. 2000, 2, 25-31.
12. Welch, T.J.; Fricke, W.F.; McDermott, P.F.; White, D.G.; Rosso, M.L.; Rasko, D.A.; Mammel, M.K.; Eppinger, M.; Rosovitz, M.J.; Wagner, D. et al. Multiple antimicrobial resistance in plague: An emerging public health risk. PLoS One 2007, 2, e309.
13. Titball, R.W.; Williamson, E.D. Yersinia pestis (plague) vaccines. Expert Opin. Biol. Ther. 2004, 4, 965-973.
14. Williamson, E.D. Plague. Vaccine 2009, 27, D56-D60.
15. Williamson, E.D.; Eley, S.M.; Stagg, A.J.; Green, M.; Russell, P.; Titball, R.W. A sub-unit vaccine elicits igg in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 1997, 15, 1079-1084.
16. Williamson, E.D.; Eley, S.M.; Stagg, A.J.; Green, M.; Russell, P.; Titball, R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 2000, 19, 566-571.
17. Feodorova, V.A.; Corbel, M.J. Prospects for new plague vaccines. Expert Rev. Vaccines 2009, 8, 1721-1738.
18. Smiley, S.T. Immune defense against pneumonic plague. Immunol. Rev. 2008, 225, 256-271.
19. Kingston, R.; Burke, F.; Robinson, J.H.; Bedford, P.A.; Jones, S.M.; Knight, S.C.; Williamson, E.D. The fraction 1 and V protein antigens of Yersinia pestis activate dendritic cells to induce primary T cell responses. Clin. Exp. immunol. 2007, 149, 561-569.
20. Williamson, E.D.; Flick-Smith, H.C.; Lebutt, C.; Rowland, C.A.; Jones, S.M.; Waters, E.L.; Gwyther, R.J.; Miller, J.; Packer, P.J.; Irving, M. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect. Immun. 2005, 73, 3598-3608.
21. Lu, S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009, 21, 346-351.
22. Wang, S.; Parker, C.; Taaffe, J.; Solorzano, A.; Garcia-Sastre, A.; Lu, S. Heterologous HA DNA vaccine prime-Inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. Vaccine 2008, 26, 3626-3633.
23. Cristillo, A.D.; Wang, S.; Caskey, M.S.; Unangst, T.; Hocker, L.; He, L.; Hudacik, L.; Whitney, S.; Keen, T.; Chou, T.H. et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006, 346, 151-168.
24. Suguitan, A.L., Jr.; Cheng, X.; Wang, W.; Wang, S.; Jin, H.; Lu, S. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza a/vietnam/1203/2004 vaccine in ferrets. PLoS One 2011, 6, e21942.
25. Wang, S.; Arthos, J.; Lawrence, J.M.; van Ryk, D.; Mboudjeka, I.; Shen, S.; Chou, T.H.; Montefiori, D.C.; Lu, S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J. Virol. 2005, 79, 7933-7937.
26. Wang, S.; Taaffe, J.; Parker, C.; Solorzano, A.; Cao, H.; Garcia-Sastre, A.; Lu, S. Hemagglutinin (HA) proteins from h1 and h3 serotypes of influenza a viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J. Virol. 2006, 80, 11628-11637.
27. Wang, S.; Mboudjeka, I.; Goguen, J.D.; Lu, S. Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines. Vaccine 2010, 28, 2011-2019.
28. Lu, S.; Manning, S.; Arthos, J. Antigen engineering in DNA immunization. Methods Mol. Med. 2000, 29, 355-374.
29. Wang, S.; Farfan-Arribas, D.J.; Shen, S.; Chou, T.H.; Hirsch, A.; He, F.; Lu, S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006, 24, 4531-4540.
30. Feltquate, D.M.; Heaney, S.; Webster, R.G.; Robinson, H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 1997, 158, 2278-2284.
31. Williamson, E.D.; Eley, S.M.; Griffin, K.F.; Green, M.; Russell, P.; Leary, S.E.; Oyston, P.C.; Easterbrook, T.; Reddin, K.M.; Robinson, A. et al. A new improved sub-unit vaccine for plague: The basis of protection. FEMS Immunol. Med. Microbiol. 1995, 12, 223-230.
32. +T-cell expression and IFN-gamma, perforin secretion for B-T constructs of F1 and V antigens of Yersinia pestis. Int. Immunopharmacol. 2013, 12, 64-73.